All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
32 matching companies
EVM18 delivers CD19 CAR mRNA in targeted LNPs. Everest’s 2026 interim results report IIT initiation in autoimmune disease and global IND preparation. EVM14 and EVM16 are cancer vaccines, not its in vivo CAR-T lead.
BR101 is a BCMA/CD19 circular mRNA in vivo CAR-T program in a registered IIT for relapsed/refractory myeloma (NCT07537049). Autoimmune development and BR102/BR103 are separately described as preclinical; their stages should not be inferred from BR101.
RXIM002 uses targeted LNPs carrying CD19 CAR circular RNA. The August 2026 update reports ongoing China IIT follow-up and FDA IND clearance for autoimmune cytopenias. It also discloses a fatal serious adverse event in a participant with systemic sclerosis; causality should not be inferred.
ModeX, an OPKO company, lists MDX3001 as in vivo CAR-T for cancer and autoimmunity. Its platform conjugates CD3×CD28 antibodies to LNPs carrying CAR mRNA. Human dosing and the program’s precise current stage were not established by the accessible pipeline text.
Thesian’s ARIANE platform uses in vivo engineering to generate CAR-T and CAR-macrophages for oncology and autoimmune disease. The company describes lentiviral engineering expertise and a dual-lineage approach. A named clinical-stage candidate and patient efficacy were not verified.
YolTech explicitly lists YOLT-401 for autoimmune disease as an in vivo CAR-T program with an undisclosed target. Its clinical gene-editing programs are separate; their stages and delivery details are not automatically assigned to YOLT-401.
Founded in 2023 and headquartered in Lexington, Mote was created by Fapon Group and Alex Wesselhoeft. Its mobilize platform enables targeted LNP/circRNA delivery. Its BIO 2026 presentation identifies a preclinical CD19/BCMA in vivo CAR-T lead; a projected November IIT is not proof of dosing.
Immunologix Laboratories offers Immunogenicity, neutralizing antibodies, PK and biomarkers. Services should be matched to the intended study and assay requirements.
Coverage expands from sourced records; this database does not claim all biopharma companies.
